Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.58 |
| ▸ | PRMT5 | O14744 | 14/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 12/20 | 0.51 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.51 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20938183 | 1.00 | ADK (0.58) | ADKPRMT5WDR77METTL3RAPGEF3 | |
| SCHEMBL20938420 | 1.00 | ADK (0.58) | ADKPRMT5WDR77METTL3RAPGEF3 | |
| SCHEMBL20419288 | 1.00 | ADK (0.58) | ADKPRMT5WDR77METTL3RAPGEF3 | |
| SCHEMBL12150813 | 1.00 | ADK (0.58) | ADKPRMT5WDR77METTL3RAPGEF3 | |
| SCHEMBL12300483 | 1.00 | ADK (0.58) | ADKPRMT5WDR77METTL3RAPGEF3 | |
| SCHEMBL23982356 | 1.00 | ADK (0.58) | ADKPRMT5WDR77METTL3RAPGEF3 | |
| SCHEMBL6731788 | 1.00 | ADK (0.58) | ADKPRMT5WDR77METTL3RAPGEF3 | |
| SCHEMBL10067814 | 0.87 | ADK (0.54) | ADKPRMT5WDR77METTL3RAPGEF3 | |
| SCHEMBL19187629 | 0.87 | ADK (0.54) | ADKPRMT5WDR77METTL3RAPGEF3 | |
| SCHEMBL14228171 | 0.87 | ADK (0.54) | ADKPRMT5WDR77METTL3RAPGEF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2360166-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | claimed |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | MERCK SHARP & DOHME LLC | 2004-06-10 | — | — | US | claimed |
| EP-4603099-A1 | ANTI-INFLUENZA VIRUS COMPOSITION, MEDICINE, FOOD, BEVERAGE, SUPPLEMENT, AGRICULTURAL CHEMICAL, FEED AND COSMETIC | Igarashi, Manabu (JP) | 2025-08-20 | — | — | EP | disclosed |
| WO-2024075794-A1 | ANTI-INFLUENZA VIRUS COMPOSITION, MEDICINE, FOOD, BEVERAGE, SUPPLEMENT, AGRICULTURAL CHEMICAL, FEED AND COSMETIC | 国立大学法人北海道大学 | 2024-04-11 | — | — | WO | disclosed |
| US-11072628-B2 | Nucleoside analogues for the treatment of parasitic infections | UNIVERSITEIT GENT (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20210024566-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS | UNIVERSITEIT GENT (BE) | 2021-01-28 | — | — | US | disclosed |
| WO-2019076633-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS | UNIVERSITEIT GENT (BE) | 2019-04-25 | — | — | WO | disclosed |
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | IONIS PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20060205686-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN | 2006-09-14 | — | — | US | disclosed |
| US-7105499-B2 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK & CO., INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN | 2005-12-08 | — | — | US | disclosed |
| US-6777395-B2 | VIRICIDES | MERCK & CO., INC. | 2004-08-17 | — | — | US | disclosed |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | MERCK SHARP & DOHME LLC | 2004-06-10 | — | — | US | disclosed |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | disclosed |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072628-B2 | Nucleoside analogues for the treatment of parasitic infections | PNP, NUDT1, SAMHD1 | ADK 109/4885PRMT5 716/4885WDR77 906/4885 |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADK 239/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | RNASE1, RNASEH1, RNASEL | ADK 325/4885PRMT5 3154/4885WDR77 1648/4885 |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | NSUN2, NSUN3, POLRMT | ADK 215/4885PRMT5 352/4885WDR77 1658/4885 |
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | POLRMT, DUT, RNASE1 | ADK 592/4885PRMT5 800/4885WDR77 2077/4885 |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADK 239/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20140309412-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | NSUN2, NSUN3, POLRMT | ADK 239/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADK 239/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADK 239/4885PRMT5 436/4885WDR77 1478/4885 |
| US-20210024566-A1 | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF PARASITIC INFECTIONS | PNP, NUDT1, SAMHD1 | ADK 109/4885PRMT5 716/4885WDR77 906/4885 |
| US-20060205686-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | ADK 239/4885PRMT5 436/4885WDR77 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.